Table 3 Changes of the echocardiographic findings in patients with cancer therapeutics-related cardiac dysfunction
Baseline | After chemotherapy | After trastuzumab therapy | |
|---|---|---|---|
LVEDVI (mL/m2) | 56.8 ± 10.6 | 57.1 ± 12.3 | 65.7 ± 12.0 |
LVESVI (mL/m2) | 19.9 ± 5.3 | 20.4 ± 6.7 | 35.0 ± 7.7†‡ |
LVEF (%) | 65.0 ± 6.4 | 64.5 ± 7.4 | 46.9 ± 4.8†‡ |
LVGLS (%) | −21.0 ± 2.4 | − 18.8 ± 2.3* | − 15.3 ± 2.6†‡ |
E (cm/sec) | 71.3 ± 10.4 | 67.5 ± 7.8 | 84.3 ± 14.7†‡ |
e’ (cm/sec) | 8.8 ± 1.4 | 7.6 ± 1.3* | 7.0 ± 0.8‡ |
s’ (cm/sec) | 7.9 ± 0.9 | 7.3 ± 1.3 | 4.5 ± 1.0†‡ |
E/e’ | 8.2 ± 1.0 | 9.0 ± 1.0 | 12.0 ± 1.4†‡ |
LAVI (mL/m2) | 25.8 ± 3.8 | 25.8 ± 3.6 | 29.1 ± 3.8†‡ |
PALS (%) | 33.1 ± 5.9 | 28.2 ± 5.5* | 23.9 ± 6.0†‡ |
LA conduit strain (%) | 19.2 ± 3.4 | 14.9 ± 2.9* | 12.7 ± 3.2‡ |
LA booster strain (%) | 13.9 ± 2.5 | 13.3 ± 2.7 | 11.2 ± 2.8‡ |
RVSP (mmHg) | 29.3 ± 7.1 | 27.1 ± 7.2 | 30.2 ± 7.9 |